Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.09B | 2.02B | 1.90B | 1.79B | 1.68B | 1.50B |
Gross Profit | 670.41M | 635.54M | 595.43M | 553.23M | 542.40M | 454.51M |
EBITDA | 118.96M | 192.84M | 44.35M | -517.28M | -9.26M | 22.13M |
Net Income | 15.35M | -10.93M | -134.52M | -662.03M | -117.04M | -57.05M |
Balance Sheet | ||||||
Total Assets | 1.66B | 1.66B | 1.61B | 1.71B | 2.33B | 1.84B |
Cash, Cash Equivalents and Short-Term Investments | 71.49M | 84.29M | 43.94M | 19.22M | 30.49M | 137.34M |
Total Debt | 1.32B | 1.33B | 1.50B | 1.36B | 1.30B | 1.23B |
Total Liabilities | 1.76B | 1.79B | 1.74B | 1.72B | 1.70B | 1.58B |
Stockholders Equity | -98.67M | -122.09M | -127.44M | -4.17M | 637.95M | 267.17M |
Cash Flow | ||||||
Free Cash Flow | 28.62M | 26.32M | 16.56M | -60.41M | -27.30M | 101.38M |
Operating Cash Flow | 35.98M | 32.64M | 22.67M | -48.40M | -11.35M | 116.62M |
Investing Cash Flow | -7.36M | -6.32M | -8.79M | -25.29M | -681.83M | -193.54M |
Financing Cash Flow | 269.00K | 14.03M | 10.85M | 62.42M | 586.33M | 210.94M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $1.13B | 27.75 | 8.37% | ― | 3.71% | 1.32% | |
71 Outperform | $1.22B | 37.09 | 6.72% | 2.23% | 14.30% | 76.89% | |
68 Neutral | $931.35M | 35.25 | 11.28% | ― | 30.04% | 43.47% | |
56 Neutral | $1.61B | ― | -91.17% | ― | 3.88% | -34.30% | |
53 Neutral | $975.47M | 287.36 | 42.49% | ― | 9.05% | ― | |
51 Neutral | $7.55B | 0.30 | -61.90% | 2.27% | 17.11% | 1.58% | |
49 Neutral | $841.88M | 18.62 | -21.08% | ― | -18.13% | -215.78% |
On June 25, 2025, Aveanna Healthcare Holdings Inc.’s subsidiaries, Aveanna Healthcare LLC and Aveanna SPV I, LLC, entered into a seventh amendment to their Receivables Financing Agreement with a bank. This amendment increased the facility limit to $275 million and extended the termination date by three years, impacting the company’s financial flexibility and operational strategy.
The most recent analyst rating on (AVAH) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Aveanna Healthcare Holdings stock, see the AVAH Stock Forecast page.
On May 9, 2025, Aveanna Healthcare Holdings Inc. conducted its 2025 Annual Meeting of Stockholders. During the meeting, three Class I directors were elected to the Board for three-year terms, Ernst & Young LLP was ratified as the independent public accounting firm for the fiscal year ending January 3, 2026, and a non-binding advisory resolution on executive compensation was approved. No other matters were addressed at the meeting.
On May 9, 2025, Aveanna Healthcare Holdings Inc. released a financial presentation to investors, emphasizing the company’s use of its website as a primary channel for distributing important information. The presentation highlighted Aveanna’s financial performance and operational statistics, including over $2.15 billion in revenue and a significant presence across 34 states with 26,500 caregivers. The company continues to focus on growth strategies and maintaining a diverse payor mix, which is crucial for its financial stability and market positioning.
Aveanna Healthcare Holdings reported a strong financial performance for the first quarter of 2025, with a 14.0% increase in revenue to $559.2 million and a significant rise in adjusted EBITDA by 93.1% compared to the previous year. The company also revised its full-year 2025 revenue guidance to exceed $2.15 billion and adjusted EBITDA to surpass $207 million, reflecting positive momentum and strategic transformations, including successful cost reductions and improved reimbursement rates.